- Home
- PYXS vs ALXO Comparison
PYXS vs ALXO Comparison
Compare PYXS & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYXS
- ALXO
- Stock Information
- Founded
- PYXS 2018
- ALXO 2015
- Country
- PYXS United States
- ALXO United States
- Employees
- PYXS N/A
- ALXO N/A
- Industry
- PYXS Biotechnology: Pharmaceutical Preparations
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- PYXS Health Care
- ALXO Health Care
- Exchange
- PYXS Nasdaq
- ALXO Nasdaq
- Market Cap
- PYXS 79.4M
- ALXO 93.7M
- IPO Year
- PYXS 2021
- ALXO 2020
- Fundamental
- Price
- PYXS $3.48
- ALXO $1.54
- Analyst Decision
- PYXS Strong Buy
- ALXO Strong Buy
- Analyst Count
- PYXS 5
- ALXO 6
- Target Price
- PYXS $7.75
- ALXO $3.30
- AVG Volume (30 Days)
- PYXS 877.2K
- ALXO 532.6K
- Earning Date
- PYXS 11-11-2025
- ALXO 11-10-2025
- Dividend Yield
- PYXS N/A
- ALXO N/A
- EPS Growth
- PYXS N/A
- ALXO N/A
- EPS
- PYXS N/A
- ALXO N/A
- Revenue
- PYXS $2,820,000.00
- ALXO N/A
- Revenue This Year
- PYXS N/A
- ALXO N/A
- Revenue Next Year
- PYXS N/A
- ALXO N/A
- P/E Ratio
- PYXS N/A
- ALXO N/A
- Revenue Growth
- PYXS N/A
- ALXO N/A
- 52 Week Low
- PYXS $0.83
- ALXO $0.40
- 52 Week High
- PYXS $5.39
- ALXO $2.27
- Technical
- Relative Strength Index (RSI)
- PYXS 60.49
- ALXO 47.86
- Support Level
- PYXS $3.17
- ALXO $1.53
- Resistance Level
- PYXS $3.75
- ALXO $1.90
- Average True Range (ATR)
- PYXS 0.31
- ALXO 0.16
- MACD
- PYXS -0.05
- ALXO -0.05
- Stochastic Oscillator
- PYXS 33.62
- ALXO 13.61
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.